Why LAM no longer applies The lactational amenorrhea method works through a neuroendocrine feedback loop: frequent suckling suppresses gonadotropin-releasing hormone (GnRH) pulses, which keeps luteinizing hormone (LH) low and prevents ovulation. However, this protection is conditional. All three criteria must be present simultaneously: no return of menses, full or nearly full breastfeeding day and night, and an infant younger than
6 months. Once any single condition fails, the method is no longer reliable. In this case, the mother is
4 months postpartum and fully breastfeeding, but her menstrual period returned
2 weeks ago.
Return of menses is the most decisive sign that ovulatory function may have resumed, so LAM must be discontinued immediately. Continuing LAM until
6 months would expose her to unintended pregnancy risk.
Choosing a hormonal method while breastfeeding The mother wants a daily pill. Two categories exist: combined oral contraceptives (COCs) containing estrogen plus progestin, and progestin-only pills (POPs). For a breastfeeding woman who is less than
6 months postpartum, the WHO medical eligibility criteria assign different categories.
Combined oral contraceptives are classified as
category 3 in this window because the estrogen component can reduce breast milk volume and alter composition, potentially compromising infant nutrition.
Progestin-only pills are classified as
category 1, meaning no restriction on use.
For a breastfeeding mother under 6 months postpartum, progestin-only pills are the preferred daily oral option because they do not interfere with milk production. The U.S. Medical Eligibility Criteria for Contraceptive Use, 2024, reaffirms this framework by systematically reviewing evidence on contraceptive safety in specific clinical contexts, including postpartum lactation
[2][3]. A Cochrane protocol on postpartum contraception in lactating individuals further highlights that comparative evaluation of combined hormonal, progestin-only, and nonhormonal methods is an active area of evidence synthesis, underscoring the clinical importance of method selection in this population .
Timing of initiation and backup contraception The mother states her period returned
2 weeks ago and she has not had intercourse since it ended. According to the U.S. Selected Practice Recommendations for Contraceptive Use, 2024, a woman may start progestin-only pills at any time if the provider is reasonably certain she is not pregnant . However, because more than
5 days have elapsed since the onset of her last menstrual period, immediate protection is not guaranteed.
Key point! She should use a backup method, such as condoms or abstinence, for the first
2 days after starting progestin-only pills. This allows sufficient time for cervical mucus thickening and endometrial changes to establish contraceptive efficacy.
Why the other options are incorrect | Option | Problem |
|---|
| 1. Start combined oral contraceptive pills now | COCs are WHO category 3 for breastfeeding women under 6 months postpartum due to risk of reduced milk supply; progestin-only is safer. |
| 2. Continue LAM until 6 months | LAM requires no return of menses; her period has already returned, so the method has failed. |
| 3. Wait until 6 months, then start combined pills | Delaying contraception leaves her unprotected now; she needs a method immediately, and progestin-only pills are category 1 even before 6 months. |
Clinical application The nurse should advise starting
progestin-only pills now, with a backup method for the first
2 days. The mother should be counseled that progestin-only pills require consistent daily dosing at approximately the same time each day for maximum effectiveness. Because she is exclusively breastfeeding, the progestin-only formulation avoids the lactation-suppressing effects of estrogen while providing reliable contraception. The 2024 U.S. MEC and SPR documents provide the evidence-based framework for this recommendation, confirming that postpartum breastfeeding status is a key determinant in contraceptive method selection and initiation timing
[2][3].
References (research sources)
- [2]
Using updated clinical recommendations to support contraceptive decision-making: U.S. medical eligibility criteria for contraceptive use, 2024.GuidelineCurtis KM, Nguyen AT, Tepper NK, Whiteman MK. (2026) · DOI: 10.1016/j.contraception.2025.111015
- [3]
U.S. Medical Eligibility Criteria for Contraceptive Use, 2024.Research articleNguyen AT, Curtis KM, Tepper NK, Kortsmit K, Brittain AW, Snyder EM (2024) · DOI: 10.15585/mmwr.rr7304a1